Crohn’s disease News and Research RSS Feed - Crohn’s disease News and Research

Telephone communication in IBD care helps to identify patients at risk of high-cost medical interventions

Telephone communication in IBD care helps to identify patients at risk of high-cost medical interventions

A comprehensive analysis of patient telephone records at an inflammatory bowel disease (IBD) clinic revealed that 15 percent of patients account for half of all calls to the clinic. Forty-two percent of frequent-caller patients also were seen in the emergency department or hospitalized within the following year. [More]
Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Children newly diagnosed with Crohn's disease may benefit from early treatment with the biologic drugs known as anti-TNF-α agents, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. [More]
Study shows high-fiber diet reduces risk of colon problems

Study shows high-fiber diet reduces risk of colon problems

Scientists have more reasons for you to eat fiber and not abuse antibiotics. [More]

Subset of TH17 cells linked to inflammation in Crohn’s disease patients, find TSRI scientists

Two-thirds to three-quarters of the estimated 700,000 Americans living with Crohn’s disease, an autoimmune condition that can disrupt the entire gastrointestinal tract, will require surgery at some point during their life. Patients and physicians often turn to this surgical intervention after a patient develops resistance to current treatments, such as steroids. [More]
TSRI scientists identify small subset of immune cells that play major role in development of Crohn's disease

TSRI scientists identify small subset of immune cells that play major role in development of Crohn's disease

Two-thirds to three-quarters of the estimated 700,000 Americans living with Crohn's disease, an autoimmune condition that can disrupt the entire gastrointestinal tract, will require surgery at some point during their life. [More]
AGA guidelines recommend anti-TNF-α biologic agents to induce remission in Crohn's disease patients

AGA guidelines recommend anti-TNF-α biologic agents to induce remission in Crohn's disease patients

The anti-TNF-α biologic agents, such as infliximab or adalimumab, are recommended to induce remission in patients with moderately severe Crohn's disease , according to a new guideline from the American Gastroenterological Association. Additionally, the guidelines recommend against using thiopurines or methotrexate alone to induce remission in these patients. The new guideline and accompanying technical review have been published in Gastroenterology, the official journal of the AGA Institute. [More]
FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. [More]

TxCell receives Manufacturing Accreditation from ANSM for cell therapy production site in France

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today that it received a Manufacturing Accreditation delivered by the French National Agency for Drug Safety. The status has been received for its cell therapy production site in Besançon, France. [More]
Keeping active reduces women’s Crohn’s risk

Keeping active reduces women’s Crohn’s risk

Regular exercise protects women against the development of Crohn’s disease, reveals research published in the BMJ. [More]
Study shows IBD patients may have increased risk of heart attack, stroke

Study shows IBD patients may have increased risk of heart attack, stroke

Patients with inflammatory bowel disease are at an increased risk of stroke and heart attack according to a new study presented by Mayo Clinic researchers at the American College of Gastroenterology's Annual Scientific Meeting, Oct. 11-16, in San Diego. [More]

Change in gene expression occurs in patients with "pouchitis" after UC surgery

"Pouchitis" developing after surgery for ulcerative colitis (UC) is associated with changes in gene expression, which increase along with disease severity, reports a study in Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America (CCFA). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health. [More]
Specialized cells play major role in inflammation that underlies Crohn's disease in small intestine

Specialized cells play major role in inflammation that underlies Crohn's disease in small intestine

​Scientists have discovered that Crohn's disease, the inflammatory bowel disorder, can originate from specialised intestinal cell type called Paneth cells. As such, they propose that small intestinal Crohn's disease might be a specific disorder of this cell type, providing a possible new target for treatments. [More]
Discovery provides additional key insights into the biology of Multiple Sclerosis

Discovery provides additional key insights into the biology of Multiple Sclerosis

A Griffith University medical scientist is part of an international team which has made a key discovery in the effort to find the cause and cure of Multiple Sclerosis. [More]

Abbvie, Galapagos Ink Up To $405M CF Collaboration

... [More]

Abbvie, Galapagos Ink Up To $405M CF Collaboration

... [More]

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

... [More]

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

... [More]
RedHill Biopharma to initiate phase III trial of RHB 104 in Crohn's disease patients

RedHill Biopharma to initiate phase III trial of RHB 104 in Crohn's disease patients

UCF College of Medicine professor Dr. Saleh Naser soon will participate in a clinical trial to test whether a new antibiotic therapy acquired by RedHill Biopharma can be used to treat Crohn's disease patients. [More]

Model including dozens of mutations helps clarify genetic factors involved in Crohn's disease

​A statistical model accounting for dozens of different genes in combination-and the interactions between them-is an important step forward in understanding the genetic factors affecting the risk of Crohn's disease (CD), reports a study in Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America (CCFA). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health. [More]

Understanding genetic factors that affect Crohn's disease risk

A statistical model accounting for dozens of different genes in combination—and the interactions between them—is an important step forward in understanding the genetic factors affecting the risk of Crohn's disease, reports a study in Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America. [More]